Trial clarifies use of blood transfusion in anaemic heart attack patients

September 02, 2020

Sophia Antipolis, France - 1 Sept 2020: Restricting blood transfusion in anaemic heart attack patients to those with very low haemoglobin levels saves blood with no negative impact on clinical outcomes. That's the finding of the REALITY trial presented in a Hot Line session today at ESC Congress 2020.1

Anaemia affects approximately 5-10% of patients with myocardial infarction and is an independent predictor of cardiac events and increased mortality. The antiplatelet and anticoagulant medications used to treat myocardial infarction raise the risk of bleeding, which in turn elevates the risk of anaemia and mortality.

However, there is uncertainty over the benefits of blood transfusion in these patients. Observational studies have reported that transfusion is associated with a higher rate of mortality in patients with myocardial infarction.2 The optimal transfusion strategy in patients with acute myocardial infarction and anaemia is also unclear. Only two very small randomised trials have been conducted, with conflicting results.3,4

REALITY is the largest randomised trial comparing a restrictive versus a liberal blood transfusion strategy in myocardial infarction patients with anaemia. In the restrictive strategy, transfusion was withheld unless haemoglobin dropped to 8 g/dL. In the liberal strategy, transfusion was given as soon as haemoglobin was 10 g/dL or below. Previous trials have compared these two strategies in other settings such as gastrointestinal bleeding, cardiac surgery or non-cardiac surgery but patients with acute myocardial infarction were excluded.

There were two primary endpoints. The primary clinical endpoint was a composite of major adverse cardiac events (MACE) at 30 days, including all-cause death, myocardial infarction, stroke, and emergency percutaneous coronary intervention (PCI) prompted by myocardial ischaemia. The cost effectiveness endpoint was the incremental cost effectiveness ratio (ICER) at 30 days.

Principal investigator Professor Philippe Gabriel Steg of Hospital Bichat, Paris, France explained the reasons for having both a clinical and cost effectiveness outcome: "Our hypothesis was that in myocardial infarction patients with anaemia, a restrictive strategy would be non-inferior to a liberal strategy with respect to clinical outcomes at 30 days but would be less costly."

The trial was conducted in 35 hospitals in France and Spain. It enrolled 668 patients with acute myocardial infarction and anaemia (haemoglobin 10 g/dL or below, but above 7 g/dL) at any time during admission. Patients were randomly allocated to the restrictive or liberal transfusion strategy and followed-up for 30 days.

The restrictive transfusion strategy was non-inferior to the liberal strategy in preventing 30-day MACE. The primary clinical outcome occurred in 36 patients (11.0%) allocated to the restrictive strategy and 45 patients (14.0%) patients allocated to the liberal strategy (difference -3.0%; 95% confidence interval [CI] -8.4% to 2.4%). The relative risk of 30-day MACE with the restrictive versus liberal strategy was 0.79.

Cost effectiveness analysis indicated that the restrictive strategy had an 84% probability of being cost-saving while improving clinical outcomes, i.e. "dominant" from a medico-economic standpoint.

Regarding safety, compared to patients receiving the liberal strategy, those allocated to the restrictive strategy were significantly less likely to develop an infection (restrictive 0.0% vs. liberal 1.5%; p=0.03) or acute lung injury (restrictive 0.3% vs. liberal 2.2%; p=0.03).

Professor Steg said: "Blood is a precious resource, and transfusion is costly, logistically cumbersome, and has side effects. The REALITY trial supports the use of a restrictive strategy for blood transfusion in myocardial infarction patients with anaemia. The restrictive strategy saves blood, is safe, and is at least as effective in preventing 30-day cardiac events compared to a liberal strategy, while saving money."

Notes to editors

Authors: ESC Press Office
Mobile: +33 (0)7 85 31 20 36

The hashtag for ESC Congress 2020 is #ESCCongress.

Follow us on Twitter @ESCardioNews

Funding: Trial funded via a grant from Programme de Recherche Médico-Economique (PRME) 2015, from the French Ministry of Health; and a grant from Instituto de Salud Carlos III (the Spanish Ministry of Economy and Competitiveness), Grant nº PI15/01543.

Disclosures: Philippe Gabriel Steg discloses:

Research grants: Bayer, Merck, Servier, Sanofi.

Speaker or consultant (including steering committee, DMC and CEC memberships): Amarin, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, BristolMyersSquibb, Idorsia, Mylan, NovoNordisk, Novartis, Pfizer, Regeneron, Sanofi, Servier.

References and notes

1Abstract title: A randomized trial of liberal vs. restrictive red blood cell transfusion strategies in patients with acute myocardial infarction and anaemia.

2Chatterjee S, Wetterslev J, Sharma A, et al. Association of Blood Transfusion With Increased Mortality in Myocardial Infarction: A Meta-analysis and Diversity-Adjusted Study Sequential Analysis. JAMA Intern Med. 2013;173:132-139.

3Cooper HA, Rao SV, Greenberg MD, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol. 2011;108:1108-1111.

4Carson JL, Brooks MM, Abbott JD, et al. Liberal Versus Restrictive Transfusion Thresholds For Patients With Symptomatic Coronary Artery Disease. Am Heart J. 2013;165:964-971.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress

ESC Congress is the world's largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2020 takes place online from 29 August to 1 September. More information is available from the ESC Press Office at

European Society of Cardiology

Related Myocardial Infarction Articles from Brightsurf:

Treatment shows reduction in heart failure after myocardial infarction
Researchers at Baylor College of Medicine identified potential preventative therapies for heart failure after a significant heart attack.

The challenges of treating acute myocardial infarction due to variant angina
In a new publication from Cardiovascular Innovations and Applications; DOI, Wen-Yuan Ding, Jia-Min Li, Fei Zheng, Li-Li Wang, Xin-Yi Wei and Guo-Hua Li from Shandong Provincial Qianfoshan Hospital, Ji'nan, China, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji'nan, China and Shandong First Medical University, Tai'an, China consider the challenges of treating acute myocardial infarction due to variant angina.

WeChat group of chest pain center for patients with acute ST-segment elevation myocardial infarction
In a new publication from Cardiovascular Innovations and Applications; DOI, Liu Yue, Qin Zhu-Yun, Yang Xin, Tang Rong and Gao Ling-Yun from the The First Affiliated Hospital of Chongqing Medical University, Chongqing, China consider the use of a social media platform (WeChat) to provide faster treatment and improve prognoses for a group of patients with acute ST-segment Elevation Myocardial Infarction.

Improved survival after obesity operation in patients with previous myocardial infarction
Researchers at Karolinska Institutet and Danderyd Hospital in Sweden have studied the risk of additional myocardial infarctions and early death in severely obese patients who undergo metabolic surgery following a myocardial event.

Researchers discover a cell type responsible for cardiac repair after infarction
The researcher of the Faculty of Science of the UMA Adrián Ruiz-Villalba, who is also member of the Andalusian Center for Nanomedicine and Biotechnology (BIONAND) and the Biomedical Research Institute of Malaga (IBIMA), is the first author of an international study that has identified the heart cells in charge of repairing the damage caused to this organ after infarction.

Discovery of cells that heal cardiac damage after infarction
Researchers at Cima and the Clinica Universidad de Navarra (Spain) have led an international study identifying the cardiac cells responsible for repairing the damage to this organ after infarction.

CHOP researchers find MIS-C associated with myocardial injury
Using sensitive parameters to assess cardiac function, researchers at Children's Hospital of Philadelphia (CHOP) have found that cardiac involvement in multisystem inflammatory syndrome in children (MIS-C) differs from Kawasaki disease (KD) and is associated with myocardial injury.

Heart attack modeled with human stem cells
A model of ischemic heart disease was developed using human induced pluripotent stem cells (hiPSC).

The relationship between lifetime drinking and non-fatal acute myocardial infarction
New research from the Prevention Research Center of the Pacific Institute for Research and Evaluation suggests that the impact of alcohol consumption on coronary heart disease may be underestimated.

The relationship between mean platelet volume and in-hospital mortality in geriatric patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Read More: Myocardial Infarction News and Myocardial Infarction Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to